Eric Morgen @ 2024 Biomarkers of Aging Conference

Eric Morgen presents how BioAge Labs is addressing metabolic diseases driven by the aging process by leveraging biomarkers of aging. He also shares updates on their leading clinical assets.
Timestamps:
[00:00:08] Biomarkers in aging clinical trials introduction
[00:01:08] How BioAge Labs tackles metabolic diseases
[00:03:15] Developing a pipeline of broad therapies, including Azelaprag harnessing the biology of human aging
[00:05:18] The BioAge Platform: Apelin signaling
[00:08:03] Biomarkers of aging to showcase Azelaprag's safety and efficacy
[00:12:10] Proteomic effects of Azelaprag
Dr. Eric Morgen is the co-founder and COO of BioAge Labs, a clinical stage biotechnology company harnessing the biology of human aging to develop new therapies for diseases. Learn more about BioAge Labs here: bioagelabs.com/